This trial will study a new drug to see if it is safe and effective in treating patients with advanced solid tumors.
- Advanced Solid Tumors
3 Primary · 17 Secondary · Reporting Duration: 2 years
2 Treatment Groups
Dose Finding as Monotherapy - Part 1
1 of 2
Expansion as Monotherapy - Part 2
1 of 2
68 Total Participants · 2 Treatment Groups
Primary Treatment: UCT-03-008 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what degree does UCT-03-008 endanger humans?
"Because of the limited data on safety and efficacy, UCT-03-008 was rated a 1 by our team at Power." - Anonymous Online Contributor
What aims are being pursued with this research endeavor?
"Over the course of two years, this trial seeks to identify a Recommended Phase 2 Dose (RP2D). Additional objectives include ascertaining Minimum Plasma UCT-03-008 Concentration at steady state (Cmin,ss), determining Time to Response (TTR) from start of treatment until either complete or partial response is achieved, and assessing Maximum Plasma UCT-03-008 Concentration at steady state (Cmax,ss)." - Anonymous Online Contributor
What is the maximum capacity of this research study?
"Affirmative. According to the clinicaltrials.gov webpage, this project is actively seeking participants and needs 68 people from 3 different sites. The trial was first made public on December 23rd 2021 and its information has been updated as recently as July 25th 2022." - Anonymous Online Contributor
Is enrollment currently available for this trial?
"Affirmative. According to clinicaltrials.gov, this medical study is actively looking for participants and was first published on December 23rd 2021 with the latest update occurring July 25th 2022. The research team seeks 68 individuals across 3 locations." - Anonymous Online Contributor